ACQUIRE BUSINESS-CRITICAL MARKET ACCESS COMPETENCIES

LEARN from Pharma's international top experts



Lieven Annemans

Critical New HTA Developments in Europe: Challenges & Solutions

Great overall introduction to the topic, with excellent details on the challenges to be dealt with in the new legislation. The interactive aspect and engaging presentation by Prof. Dr Lieven Annemans, an obvious expert, were particularly valuable. The course deepened my understanding of HTA and provided a comprehensive overview of the topic."

Laura Bauer, Senior Manager, Global Policy & External Affairs - Merck (Germany)



Critical New HTA Developments in Europe: Challenges & Solutions

LEARN

- > The different types of HTAs in Europe.
- > How to address the broad and evolving range of assessment criteria in Europe.
- > How to optimise clinical evidence generation for HTA bodies.
- > How to use Real-World Data for HTA purposes.
- > How to prepare for the Joint Clinical Assessment (JCA) in the EU.



The Expert
Lieven Annemans

- Prof. Dr Lieven Annemans has participated in more than 400 health economic evaluations in over 20 countries across a wide spectrum of therapeutic areas.
 He has also been involved as an expert in a large number of Health Technology Assessments (HTAs) and is actively involved in HTA on a European level.
- Lieven has a unique profile: academic professor, past-president of ISPOR, author of *Health economics for non-economists* (Pelckmans Pro, 2018), trainer and consultant.
- Highly respected for his vast international and cross-therapeutic experience, Lieven is a sought-after advisor and educator to health policy makers and the innovative healthcare industry.
- Lieven has been on CELforPharma's faculty since 2009 and is always applauded by participants for his engaging and fun teaching style.

Dates & Locations

11 December 2025 (live online)

Visit www.celforpharma.com for registration fees and updates.

What Participants Say About This Course

Great overall introduction to the topic, with excellent details on the challenges to be dealt with in the new legislation. The interactive aspect and engaging presentation, were particularly valuable. The course deepened my understanding of HTA and provided a comprehensive overview."

Merck
Laura Bauer
Senior Manager, Global Policy &
External Affairs
Germany (June 2024)

The course and instructor were great.
Lieven is clearly an expert in the field,
with clear and articulate presentations.
The interactions between attendees
added to the experience, and I have
gained valuable insights into the
upcoming EU HTA changes. Highly
recommended!"

Novartis Nick Riley Senior Market Access Manager Australia (June 2024) Great lecturer; the information covered during the training was very comprehensive, addressing both the basics and the latest developments. The overview of different models used in different EU countries was extremely valuable and the participant engagement in discussions was enriching."

Insuvia Monika Staniulyte Regulatory Affairs Team Lead Lithuania (June 2024)





All courses are held in CET/Brussels Time. Please check the Dates & Locations section on our website for the exact start and end times, or send an email to margherita.mutto@celforpharma.com.

> Welcome & Introductions (~15 min)

Definitions and Taxonomy of HTA (~1 h)

- Definitions: what HTA is and what it is not
- Relationship and differences between HTA, health economic evaluations, and outcomes research
- Different types of HTAs used for health technologies (such as medicines, medtech solutions, and others) and the wide variety across countries

> Optimising the Mix of Criteria: Challenges & Solutions (~1 h 30 min)

- The 10 possible criteria in the assessment of new health technologies and their relative weight
- Challenging the QALY and going beyond the QALY
- Evolution in the key criteria used by different HTA bodies
- Dos and don'ts for addressing the different criteria

> Generating Clinical Evidence: Challenges & Solutions (~45 min)

- Evidence requirements by HTA bodies and payers: a moving target
- The changing nature of clinical trials
- How to optimise the evidence generation plan
- How early dialogues and advice can increase HTA success rates

Lunch Break

> The Increasing Need for Real World Data: Challenges & Solutions (~1 h 15 min)


- Why Real-World Data is being used more and more for HTA purposes
- Benefits of Real-World Data throughout the lifecycle of health technologies
- Getting real on Real-World Data: dos and don'ts

> Towards a Joint Clinical Assessment (JCA) in the EU: Challenges & Solutions (~1 h 30 min)

- A brief history and a look forward
- Pros & cons of JCA from different viewpoints (industry, payers, policy makers, patients, etc.)
- Anticipating JCA: dos and don'ts

> Summary & Final Discussion (~15 min)

Registration Form





QUESTIONS?

Annelies Swaan aswaan@celforpharma.com

Course(s)	
Course Title	
Course Date(s)	
Registration Fee	
Visit our website www.celforpharma.com	for information about the early bird fee and full fee, group discounts, etc.
Participant Details	
Title	Email
First Name	
Last Name	Country of Work
Job Title	
Company Details	
Company Name	
VAT Number	
Invoicing Address:	
Street Address	
•	
Country	
Payment	
Payment Method 🔲 Bank Tra	ansfer (+3%) 🔲 Credit Card
PO Number (optional)	
Confirm Registration	
In order to complete the registration, ple	ease tick the following box(es):
I, the participant(s), have read and ac	
	.celforpharma.com/transfer-cancellation-policy)
and Privacy Policy (www.celforpharm	• • • • • • • • • • • • • • • • • • • •
☐ Laccent that CEL for Dharma requirely	cande ma information by amail on topics discussed within their website.
	sends me information by email on topics discussed within their website at to my function, under the condition that I can unsubscribe at any time.
· · · · · · · · · · · · · · · · · · ·	are stored in a database for that purpose, as per CELforPharma's
·	m/we-value-your-privacy), of which I accept the terms.